PuraPly SX
PuraPly SX

POWER OFPLUS

FOUR-LAYER ECM SCAFFOLD + PHMB FOR DEEP, COMPLEX WOUNDs1

To support healing and aid in granulation tissue formation2

Native, cross-linked ECM scaffold1,3

  • Four layers of native, cross-linked ECM scaffold1,3:
    • Maximize surface area for PHMB saturation1,3,4
    • More layers support product durability5
    • Quench excess protease activity and resist degradation3,4,6
    • Provide a scaffold for cellular migration and proliferation6

Broad-spectrum PHMB7

  • PHMB antimicrobial provides a persistent antimicrobial effect in the product that inhibits a broad spectrum of microbes7,8
  • High tissue compatibility and low cytotoxicity7-9
  • Positively charged PHMB specifically targets and kills negatively charged bacterial cells3,7,9

Unique combination helps address challenges to healing or creating a viable wound bed for definitive closure.1,3

ECM=extracellular matrix; MMPs=matrix metalloproteinases; PHMB=polyhexamethylene biguanide

RANGE OF SIZES AND CONFIGURATIONS

Product NumberDescriptionTotal Size (cm2)UDI
515-055PuraPly SX 5x52500618474000497
515-057PuraPly SX 6x95400618474000503
515-073PuraPly SX 8x1612800618474000534
515-075PuraPly SX 10x2020000618474000541

PROTECT COMPLEX SURGICAL WOUNDS FROM DAY ONE1

Native, cross-linked ECM scaffold + broad-spectrum PHMB antimicrobial1,3,7

Complex surgical wounds are generally left open to heal or until a viable wound bed is established that enables surgeons to achieve definitive closure (flap, graft, secondary intention).10

Healing is complicated by11-16:

Bioburden + Biofilm
Wound depth
Shape irregularity
Loss of subcutaneous tissue

POST-SURGICAL BIOBURDEN MANAGEMENT

After the operating room, bioburden management may be necessary to help mitigate the risk of complications in a variety of complex surgical wounds such as fasciotomies and more11:

Plastic surgery:

Preparation for split-thickness skin graft or flap procedure, pressure injuries, and degloving injuries

General surgery:

Surgical dehiscence, pressure injuries, and trauma wounds

Orthopedic surgery:

Open fractures and trauma wounds

Vascular surgery:

Venous leg ulcers and complex limb salvage

Leg tumor excision site Leg tumor excision site
Pressure injury Pressure injury

Images courtesy of Vipul Dev, MD

BIOBURDEN AND BIOFILM CAN DELAY HEALING17-20

All open wounds are at risk of contamination—without proper control of bioburden, infection and/or biofilm may develop.17,21

Elevated bioburden can lead to biofilm, which may trigger inflammation that delays healing.17-20

BIOBURDEN AND BIOFILM CAN DELAY HEALING

DEBRIDEMENT ALONE IS NOT ENOUGH17,22

DEBRIDEMENT ALONE IS NOT ENOUGH

Aggressive debridement is essential to remove bioburden and biofilm, but biofilm re-forms rapidly.17,22

PROTECT WITH PURPOSE

PuraPly SX can be used adjunctly with PuraPly MZ.

PuraPly SX has a broad-spectrum antimicrobial effect within the product to control bioburden.1,7

PuraPly MZ, with micronized, native collagen matrix, optimizes contact with the wound bed and supports a healing environment.23,24

PuraPly SX
PuraPly SX
+
PuraPly MZ
PuraPly MZ

See how PuraPly SX helps protect surgical wounds and support healing.

Learn more about PuraPly MZ

Visit PuraPly MZ Page
Download the Brochure
Please refer to the PuraPly SX Instructions for Use for complete prescribing information.

References:

  1. PuraPly Antimicrobial Surgical Wound Matrix [package insert]. Canton, MA: Organogenesis Inc; 2023.
  2. Bain MA, et al. J Comp Eff Res. 2020;9(10):691-703.
  3. Brantley J, et al. Wounds Int. 2016;7(3):1-5.
  4. Carpenter S, et al. Wounds. 2016;28(6 suppl):S1-S20.
  5. Data on file. PX_DR-0002. Organogenesis Inc.
  6. Data on file. PDR-0005. Organogenesis Inc.
  7. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
  8. Davis SC, et al. Int Wound J. 2022;19(1):86-99.
  9. Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715.
  10. Hall J, et al. Wound Repair Regen. 2014;22(6):694-700.
  11. Delmore B, et al. Adv Skin Wound Care. 2017;30(6):272-286.
  12. Ferreira MC, et al. Clinics (Sao Paulo). 2006;61(6):571-578.
  13. Bowler PG, et al. Clin Microbiol Rev. 2001;14(2):244-269.
  14. Myers BA. Wound management principles and practice. 4th ed. Upper Saddle River, NJ: Pearson; 2020.
  15. Cardinal M, et al. Wound Repair Regen. 2009;17(2):173-178.
  16. McGrath MH, et al. Plast Reconstr Surg. 1983;72(1):66-73.
  17. Schultz G, et al. Wound Repair Regen. 2017;25(5):744-757.
  18. Frykberg RG, et al. Adv Wound Care. 2015;4(9):560-582.
  19. Schultz GS, et al. Wound Rep Regen. 2003;11(suppl 1):S1-S28.
  20. Gibson D, et al. Wounds Int. 2009;1(1):1-6.
  21. International Wound Infection Institute (IWII). Wound infection in clinical practice. Wounds International. 2022.
  22. Wolcott RD, et al. J Wound Care. 2010;19(8):320-328.
  23. PuraPly Micronized [package insert]. Canton, MA: Organogenesis Inc; 2022.
  24. Data on file. PMZ_DR-0001. Organogenesis Inc.

LEARN ABOUT THE POWER OF PLUS FOR COMPLEX SURGICAL WOUNDS

CONTACT US.

All fields required unless marked optional

We're sorry, it looks like something isn't right. Please see below.

THANK YOU

Your information has been received.